Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multifactorial treatment is necessary to improve long-term outcomes as stated in treatment guidelines [1,5,6].”
The cited source says what the claim attributes to it.
In the citing paper
“Type 2 diabetes is a complex disease [1,2] with an increasing prevalence worldwide [3,4].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · cited 7×
“In the UK Prospective Diabetes Study (UKPDS) [30, 31], patients with newly diagnosed type 2 diabetes were randomised to two treatment policies.”
BackgroundInfluentialCrossing the Quality Chasm: A New Health System for the 21st Century
Baker, A. (2001) · BMJ · doi:10.1136/bmj.323.7322.1192 · Cited by 10,736
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“It is well established that the risk of microvascular and macrovascular complications is related to glycaemia, as measured by HbA1c; this remains a major focus of therapy [29].”
BackgroundTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · cited 2×
“By contrast, substantially fewer metformin-treated patients experienced myocardial infarction, diabetes-related and all-cause mortality [32], despite a mean HbA1c only 0.”
BackgroundEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The UKPDS 10‐year follow-up demonstrated that the relative benefit of having been in the intensive management policy group was maintained over a decade, resulting in the emergence of statistically significant benefits on cardiovascular disease (CVD) endpoints and total mortality in those initially assigned to sulfonyl…”
BackgroundSelf-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 1×
“Modified-Release Controlled Evaluation [ADVANCE] [35], Veterans Affairs Diabetes Trial [VADT] [36]) reported the effects of two levels of glycaemic control on cardiovascular”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 3×
“It may therefore also be considered, unless heart failure is present [60].”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“duced more recently [63].”
Self-citationBasevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 13×
“Recognised side effects of TZDs include weight gain, fluid retention leading to oedema and/or heart failure in predisposed individuals and increased risk of bone fractures [57, 60].”
BackgroundInfluentialStandards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“The majority of patients are able to stop some, or even all, of their anti-hyperglycaemic medications, although the durability of this effect is not known [105].”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 1×
“Indeed, while matching a drug’s mechanism of action to the underlying causes of hyperglycaemia in a specific patient seems logical, there are few data that compare strategies based on this approach [109].”
BackgroundPark, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074 · cited 2×
“While certain racial/ethnic features that increase the risk of diabetes are well recognised (greater insulin resistance in Latinos [107], more beta cell dysfunction in East Asians [108]), using this information to craft optimal therapeutic strategies is in its infancy.”
BackgroundBoulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001) · JAMA · doi:10.1001/jama.286.10.1218 · Cited by 1,889
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Bantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795 · cited 1×
“Dietary advice must be personalised [49].”
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationMusso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293 · cited 1×
“There is preliminary evidence that patients with fatty liver may benefit from treatment with pioglitazone [45, 127, 128].”
BackgroundBooth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189 · cited 2×
“Finally, a meta-analysis of cardiovascular outcomes in these trials suggested that every HbA1c reduction of ~1%may be associated with a 15% relative risk reduction in non-fatal myocardial infarction, but without benefits on stroke or allcause mortality [36].”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“two-drug combination that is not yet or no longer achieving the glycaemic target [83–86].”
BackgroundOral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035 · cited 1×
“aged patients—threefold that associated with conventional therapy [129].”
BackgroundGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942 · cited 1×
“isations [10] and by other societies and federations [2, 11–15].”
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“It remains unknown whether hypoglycaemia was the cause of the increased mortality in the intensive group [130, 131].”
BackgroundSelf-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881 · cited 1×
“Glycaemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available [1–5], mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycaemic control o…”
BackgroundSelf-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“two-drug combination that is not yet or no longer achieving the glycaemic target [83–86].”
BackgroundSelf-citationA self-regulation program for maintenance of weight loss
Wing, R. R., Tate, D. F., Gorin, A. A., Raynor, H. A., & Fava, J. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061883 · Cited by 830 · cited 1×
“High-energy foods, including those rich in saturated fats, and sweet desserts and snacks should be eaten less frequently and in lower amounts [50–52].”
BackgroundBolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823 · cited 1×
“5%) [1, 69, 70], and generally lower for meglitinides, DPP-4 inhibitors, AGIs, colesevelam and bromocriptine (~0.”
BackgroundHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“as normal a glycaemic profile as possible without unacceptable weight gain or hypoglycaemia [73].”
BackgroundBooth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 783 · cited 1×
“Older adults (>65–70 years) often have a higher atherosclerotic disease burden, reduced renal function, and more comorbidities [99, 100].”
BackgroundGuyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Cook, D. J., Green, L., Naylor, C. D., Wilson, M. C., Richardson, W. S., & for the Evidence-Based Medicine Working Group (2000) · JAMA · doi:10.1001/jama.284.10.1290 · Cited by 748 · cited 1×
“Patient involvement in the medical decision-making constitutes one of the core principles of evidence-based medicine, which mandates the synthesis of best available evidence from the literature with the clinician’s expertise and patient’s own inclinations [26].”
BackgroundWe need minimally disruptive medicine
May, C., Montori, V. M., & Mair, F. S. (2009) · BMJ · doi:10.1136/bmj.b2803 · Cited by 734 · cited 1×
“should also be considered, since the achievement of any degree of glucose control requires active participation and commitment [19, 23, 45, 46].”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · cited 2×
“isations [10] and by other societies and federations [2, 11–15].”
BackgroundSelf-citationLago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710 · cited 1×
“TZDs should be avoided [117, 118].”
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · cited 2×
“and/or symptomatic, a ‘basal’ insulin alone is typically added [74].”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Paget's Disease of the Mandible
Patel, M. B., & Bhalla, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmicm066227 · Cited by 610
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609 · cited 12×
“There is a sig - nificant need for high - quality comparative - effectiveness research , not only regarding glycaemic control , but also costs and those outcomes that matter most to patients— quality of life and the avoidance of morbid and life - limiting complications , especially CVD [ 19 , 23 , 70 ] .”
BackgroundInfluentialElmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., Lin, P.-H., Champagne, C., Harsha, D. W., Svetkey, L. P., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00007 · Cited by 596 · cited 1×
“High-energy foods, including those rich in saturated fats, and sweet desserts and snacks should be eaten less frequently and in lower amounts [50–52].”
BackgroundNissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594 · cited 1×
“Another agent of this class, rosiglitazone, is no longer widely available owing to concerns of increased myocardial infarction risk [61].”
BackgroundUK prospective diabetes study (UKPDS): VIII. Study design, progress and performance
UK Prospective Diabetes Study Group (1991) · Diabetologia · doi:10.1007/bf00400195 · Cited by 543
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationKlein, S., Sheard, N. F., Pi-Sunyer, X., Daly, A., Wylie-Rosett, J., Kulkarni, K., & Clark, N. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2067 · Cited by 540
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525 · cited 4×
“CKD, chronic kidney disease; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase IV; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide 1; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; PPAR, peroxisome proliferator-activated receptor; ProACTIVE, Prospective Pioglitazone Clinical Trial i…”
BackgroundInfluentialEpidemiology and Natural History of NAFLD and NASH
Ong, J. P., & Younossi, Z. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.009 · Cited by 457 · cited 1×
“Liver dysfunction Individuals with type 2 diabetes frequently have hepatosteatosis as well as other types of liver disease [126].”
BackgroundImportance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies
Anderson, J. W., Kendall, C. W. C., & Jenkins, D. J. A. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719316 · Cited by 448
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447 · cited 1×
“Of note, the dosing of these basal insulin analogues may differ, with most comparative trials showing a higher average unit requirement with insulin detemir [77].”
BackgroundKaragiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Self-citationUse of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432 · cited 1×
“harm from using metformin [124, 125].”
Self-citationIndividualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386 · cited 7×
“5% [42–48 mmol/mol]) might be considered in selected patients (with short disease duration, long life expectancy, no significant CVD) if this can be achieved without significant hypoglycaemia or other adverse effects of treatment [20, 43].”
BackgroundMethodInfluentialSelf-citationLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364 · cited 2×
“Thiazolidinediones (TZDs) are peroxisome proliferatoractivated receptor γ activators [59] that improve insulin sensitivity in skeletal muscle and reduce hepatic glucose production [54, 55].”
BackgroundNyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343 · cited 2×
“D ia be te s S tu dy [ 29 –3 3] ? ac tiv at io n Diabetologia (2012) 55:1577–1596 1585”
BackgroundGlycemic Control, Complications, and Death in Older Diabetic Patients
Huang, E. S., Liu, J. Y., Moffet, H. H., John, P. M., & Karter, A. J. (2011) · Diabetes Care · doi:10.2337/dc10-2377 · Cited by 343 · cited 1×
“Chronic kidney disease Kidney disease is highly prevalent in type 2 diabetes, and moderate to severe renal functional impairment (eGFR <60 ml/min) occurs in approximately 20– 30% of patients [121, 122].”
BackgroundImprovement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314 · cited 1×
“on higher doses, increments of 5–10%) to the daily dose once or twice weekly if the fasting glucose levels are above the pre-agreed target is a reasonable approach [89].”
BackgroundEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 1×
“Data concerning the glycaemic benefits of incretin-based therapy combined with basal insulin are accumulating; combination with GLP1 receptor agonists may be helpful in some patients [97, 98].”
BackgroundNauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295 · cited 2×
“GLP-1 receptor agonists are associated with weight reduction [38], which in some patients may be substantial.”
BackgroundSelf-citationZinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290
Self-citationThe Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.293 · Cited by 283 · cited 2×
“During the clinical encounter, the patient’s preferred level of involvement should be gauged and therapeutic choices explored, potentially with the utilisation of decision aids [21].”
BackgroundBromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
DeFronzo, R. A. (2011) · Diabetes Care · doi:10.2337/dc11-0064 · Cited by 257
Patient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252 · cited 10×
“There is a sig - nificant need for high - quality comparative - effectiveness research , not only regarding glycaemic control , but also costs and those outcomes that matter most to patients— quality of life and the avoidance of morbid and life - limiting complications , especially CVD [ 19 , 23 , 70 ] .”
BackgroundInfluentialLoke, Y. K., Kwok, C. S., & Singh, S. (2011) · BMJ · doi:10.1136/bmj.d1309 · Cited by 245 · cited 1×
“Fluid retention may pose a clinical or merely an aesthetic problem [82].”
BackgroundTriple Therapy in Type 2 Diabetes
Rosenstock, J., Sugimoto, D., Strange, P., Stewart, J. A., Soltes-Rak, E., Dailey, G., & on behalf of the Insulin Glargine 4014 Study Investigators (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-0695 · Cited by 235
Sosnowski, C., & Janeczko-Sosnowska, E. (2007) · PubMed · Cited by 235
Avilés-Santa, L., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 225 · cited 1×
“Metformin is often continued when basal insulin is added, with studies demonstrating less weight gain when the two are used together [95].”
BackgroundEffectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes
Unick, J. L., Beavers, D., Jakicic, J. M., Kitabchi, A. E., Knowler, W. C., Wadden, T. A., Wing, R. R., & for the Look AHEAD Research Group (2011) · Diabetes Care · doi:10.2337/dc11-0874 · Cited by 218 · cited 1×
“diovascular risk factors for relatively small changes in body weight [103].”
BackgroundGaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
Abstracts of the IDF Congress in Paris 2003
(2003) · Diabetologia · doi:10.1007/s00125-003-1190-9 · Cited by 211
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
(1991) · PubMed · Cited by 191
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187 · cited 1×
“Asmentioned, cardiovascular effects of incretin-based therapies, including those on ventricular function, are currently under investigation [120].”
BackgroundSelf-citationAdjust to Target in Type 2 Diabetes
Bergenstal, R. M., Johnson, M., Powers, M. A., Wynne, A., Vlajnic, A., Hollander, P., & Rendell, M. (2008) · Diabetes Care · doi:10.2337/dc07-2137 · Cited by 181
Self-citationThe Stunned β Cell: A Brief History
Ferrannini, E. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.009 · Cited by 175
Self-citationGreenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-12-200912150-00005 · Cited by 170 · cited 1×
“specific role of each drug, the patient and disease factors that drive clinical decision-making [20–23] and the constraints imposed by age and co-morbidity [4, 6].”
BackgroundUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationContraindications can damage your health—is metformin a case in point?
Holstein, A., & Stumvoll, M. (2005) · Diabetologia · doi:10.1007/s00125-005-0026-1 · Cited by 165 · cited 1×
“[123].”
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 161 · cited 1×
“of glycaemic control, recent evidence concerning efficacy and safety of several new drug classes [16, 17], the withdrawal/restriction of others and increasing calls for”
BackgroundThe case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157 · cited 1×
“Since hypoglycaemia may exacerbate myocardial ischaemia and may cause dysrhythmias [111], it follows that medications that”
BackgroundLiesegang, T. J. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00911-9 · Cited by 152
Gross, J. L., Kramer, C. K., Leitão, C. B., Hawkins, N., Viana, L. V., Schaan, B. D., Pinto, L. C., Rodrigues, T. C., Azevedo, M. J., & for the Diabetes and Endocrinology Meta-analysis Group (DEMA)* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-10-201105170-00007 · Cited by 150 · cited 1×
“On average, any second agent is typically associated with an approximate further reduction in HbA1c of ~1% (11 mmol/ mol) [70, 79].”
BackgroundChen, K.-W., Boyko, E. J., Bergstrom, R. W., Leonetti, D. L., Newell-Morris, L., Wahl, P. W., & Fujimoto, W. Y. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.747 · Cited by 144 · cited 2×
“While certain racial/ethnic features that increase the risk of diabetes are well recognised (greater insulin resistance in Latinos [107], more beta cell dysfunction in East Asians [108]), using this information to craft optimal therapeutic strategies is in its infancy.”
BackgroundInitiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani, A. A., Varughese, G. I., Scarpello, J. H., & Hanna, F. W. F. (2007) · BMJ · doi:10.1136/bmj.39255.669444.ae · Cited by 138 · cited 1×
“Metformin, previously contraindicated in heart failure, can now be used if the ventricular dysfunction is not severe, if patient’s cardiovascular status is stable and if renal function is normal [119].”
BackgroundKoro, C. E., Lee, B. H., & Bowlin, S. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.020 · Cited by 137 · cited 1×
“Chronic kidney disease Kidney disease is highly prevalent in type 2 diabetes, and moderate to severe renal functional impairment (eGFR <60 ml/min) occurs in approximately 20– 30% of patients [121, 122].”
BackgroundThe Relationship Between Glycemic Control and Falls in Older Adults
Nelson, J. M., Dufraux, K., & Cook, P. F. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01430.x · Cited by 133 · cited 1×
“They are also more likely to be compromised by hypoglycaemia; for example, unsteadiness may result in falls and fractures [101], and a tenuous cardiac status may deteriorate into catastrophic events.”
BackgroundInsulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Bryan, J., Crane, A., Vila-Carriles, W., Babenko, A., & Aguilar-Bryan, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054546879 · Cited by 133 · cited 1×
“Through the closure of ATP-sensitive potassium channels on beta cells, these drugs stimulate insulin release [56].”
BackgroundDiabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly
Berlie, H. D., & Garwood, C. L. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m551 · Cited by 131 · cited 1×
“Hypoglycaemia may lead to dysrhythmias, but can also lead to accidents and falls (which are more likely to be dangerous in the elderly) [132], dizziness (leading to falls), confusion (so other therapies may not be taken or taken incorrectly) or infection (such as aspiration during sleep, leading to pneumonia).”
BackgroundColesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130 · cited 1×
“Two agents that are used infrequently in the USA and Europe are the α-glucosidase inhibitors (AGIs), which retard gut carbohydrate absorption [65], and colesevelam, a bile acid sequestrant whose mechanism of glucose-lowering action remains poorly understood and whose major additional benefit is LDL-cholesterol reducti…”
BackgroundIncretin mimetics as a novel therapeutic option for hepatic steatosis
Tushuizen, M. E., Bunck, M. C., Pouwels, P. J., Van Waesberghe, J. H. T., Diamant, M., & Heine, R. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01315.x · Cited by 129 · cited 1×
“There is preliminary evidence that patients with fatty liver may benefit from treatment with pioglitazone [45, 127, 128].”
BackgroundSelf-citationDavis, T. M. E., Wright, A. D., Mehta, Z., Cull, C. A., STRATTON, I. M., Bottazzo, G. F., Bosi, E., Mackay, I. R., & Holman, R. R. (2005) · Diabetologia · doi:10.1007/s00125-005-1690-x · Cited by 126 · cited 1×
“These individuals, while presenting with mild hyperglycaemia, often responsive to oral agents, eventually develop more severe hyperglycaemia and require intensive insulin regimens [106].”
BackgroundWhere Is the Patient in Diabetes Performance Measures?
Glasgow, R. E., Peeples, M., & Skovlund, S. E. (2008) · Diabetes Care · doi:10.2337/dc07-1845 · Cited by 125 · cited 11×
“There is a sig - nificant need for high - quality comparative - effectiveness research , not only regarding glycaemic control , but also costs and those outcomes that matter most to patients— quality of life and the avoidance of morbid and life - limiting complications , especially CVD [ 19 , 23 , 70 ] .”
BackgroundInfluentialIncretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119 · cited 1×
“5%) [1, 69, 70], and generally lower for meglitinides, DPP-4 inhibitors, AGIs, colesevelam and bromocriptine (~0.”
BackgroundSelf-citationGerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116 · cited 1×
“Shorter-acting secretagogues, the meglitinides (or glinides), stimulate insulin release through similar mechanisms but may be associated with less hypoglycaemia [58].”
BackgroundVan de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., & De Grauw, W. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005061.pub2 · Cited by 115 · cited 1×
“Two agents that are used infrequently in the USA and Europe are the α-glucosidase inhibitors (AGIs), which retard gut carbohydrate absorption [65], and colesevelam, a bile acid sequestrant whose mechanism of glucose-lowering action remains poorly understood and whose major additional benefit is LDL-cholesterol reducti…”
BackgroundManagement of type 2 diabetes: summary of updated NICE guidance
Home, P., Mant, J., Diaz, J., & Turner, C. (2008) · BMJ · doi:10.1136/bmj.39560.442095.ad · Cited by 108 · cited 1×
“isations [10] and by other societies and federations [2, 11–15].”
BackgroundDavidson, M. B., Raskin, P., Tanenberg, R. J., Vlajnic, A., & Hollander, P. (2011) · Endocrine Practice · doi:10.4158/ep10323.or · Cited by 107 · cited 3×
“Therefore, this strategy is somewhat inflexible but may be appropriate for certain patients who eat regularly and may be in need of a simplified approach beyond basal insulin [92, 93].”
BackgroundSluik, D., Boeing, H., Montonen, J., Pischon, T., Kaaks, R., Teucher, B., Tjonneland, A., Halkjaer, J., Berentzen, T. L., Overvad, K., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr048 · Cited by 102 · cited 1×
“The majority of individuals with type 2 diabetes are overweight or obese (~80%) [102].”
Smith, R. J., Nathan, D. M., Arslanian, S. A., Groop, L., Rizza, R. A., & Rotter, J. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1966 · Cited by 100 · cited 1×
“Even if such evidence were available, the data would show median responses and not address the vital question of who responded to which therapy and why [24].”
BackgroundOwens, D. R., Luzio, S. D., Sert‐Langeron, C., & Riddle, M. C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99 · cited 1×
“This is suggested when the fasting glucose is at target but the HbA1c remains above goal after 3–6 months of basal insulin titration [91].”
BackgroundDiabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 97 · cited 1×
“Heart failure With an ageing population and recent decreases in mortality after myocardial infarction, the diabetic patient with progressive heart failure is an increasingly common scenario [116].”
BackgroundSelf-citationSchernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97 · cited 1×
“specific role of each drug, the patient and disease factors that drive clinical decision-making [20–23] and the constraints imposed by age and co-morbidity [4, 6].”
BackgroundMetformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Nye, H. J., & Herrington, W. G. (2011) · Nephron Clinical Practice · doi:10.1159/000323739 · Cited by 92 · cited 1×
“harm from using metformin [124, 125].”
Ilag, L. L., Kerr, L., Malone, J. K., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.003 · Cited by 90 · cited 1×
“In general, when compared with basal insulin alone, pre-mixed regimens tend to lower HbA1c to a larger degree, but often at the expense of slightly more hypoglycaemia and weight gain [94].”
ResultAcarbose: oral antidiabetes drug with additional cardiovascular benefits
Hanefeld, M., & Schaper, F. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.2.153 · Cited by 87 · cited 6×
“[1] [69] [70], and generally lower for meglitinides, DPP-4 inhibitors, AGIs, colesevelam and bromocriptine (~0.5–1.0%).”
BackgroundInfluentialCurrent treatment of non‐alcoholic fatty liver disease
Ahmed, M. H., & Byrne, C. D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00926.x · Cited by 84
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 84 · cited 1×
“The amylin agonist, pramlintide, is typically reserved for patients treated with intensive insulin therapy, usually in type 1 diabetes mellitus; it decreases postprandial glucose excursions by inhibiting glucagon secretion and slowing gastric emptying [68].”
BackgroundBlonde, L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.005 · Cited by 82 · cited 1×
“If monotherapy alone does not achieve/maintain an HbA1c target over ~3 months, the next step would be to add a second oral agent, a GLP-1 receptor agonist or basal insulin [5, 10].”
BackgroundType 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 77 · cited 2×
“isations [10] and by other societies and federations [2, 11–15].”
BackgroundSelf-citationRiveline, J., Danchin, N., Ledru, F., Varroud-Vial, M., & Charpentier, G. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70030-7 · Cited by 76 · cited 1×
“ditioning [112], but the actual clinical relevance of this remains unproven.”
BackgroundMurad, M. H., Shah, N. D., Houten, H. K. V., Ziegenfuss, J. Y., Deming, J. R., Beebe, T. J., Smith, S. A., Guyatt, G. H., & Montori, V. M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.005 · Cited by 74 · cited 1×
“a move towards more patient-centred care [18, 19].”
Goals of Glycemic Control in Frail Older Patients With Diabetes
Lee, S. J. (2011) · JAMA · doi:10.1001/jama.2011.404 · Cited by 70 · cited 1×
“doses of multiple glucose-lowering agents, including insulin [20, 44].”
BackgroundRoberts, V. L., Stewart, J. A., Issa, M., Lake, B., & Melis, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.017 · Cited by 68
Treatment of Patients Over 64 Years of Age With Type 2 Diabetes
Del Prato, S., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2075 · Cited by 64 · cited 1×
“Older adults (>65–70 years) often have a higher atherosclerotic disease burden, reduced renal function, and more comorbidities [99, 100].”
BackgroundAkalin, S., Berntorp, K., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C. S., Pan, C. Y., Rosenthall, W., Shestakova, M., et al. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02165.x · Cited by 60 · cited 1×
“5% [42–48 mmol/mol]) might be considered in selected patients (with short disease duration, long life expectancy, no significant CVD) if this can be achieved without significant hypoglycaemia or other adverse effects of treatment [20, 43].”
Background7 Insulin action and substrate competition
Groop, L., & Ferrannini, E. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80243-5 · Cited by 54 · cited 1×
“Moreover, an increased delivery of fatty acids to the liver favours their oxidation, which contributes to increased gluconeogenesis, whereas the absolute overabundance of lipids promotes hepatosteatosis [41].”
BackgroundSelf-citationN of 1 trials in diabetes: making individual therapeutic decisions
Τσάπας, Α., & Matthews, D. R. (2008) · Diabetologia · doi:10.1007/s00125-008-0983-2 · Cited by 53 · cited 1×
“In a shared decision-making approach, clinician and patient act as partners, mutually exchanging information and deliberating on options, in order to reach a consensus on the therapeutic course of action [27].”
BackgroundSelf-citationGordon, N. F., Salmon, R. D., Franklin, B. A., Sperling, L. S., Hall, L. K., Leighton, R. F., & Haskell, W. L. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.039 · Cited by 53 · cited 1×
“High-energy foods, including those rich in saturated fats, and sweet desserts and snacks should be eaten less frequently and in lower amounts [50–52].”
BackgroundReview article: Thiazolidinediones and heart failure
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338772 · Cited by 50 · cited 1×
“TZDs should be avoided [117, 118].”
Translating Comparative Effectiveness Into Practice: The Case of Diabetes Medications
Shah, N. D., Mullan, R. J., Breslin, M., Yawn, B. P., Ting, H. H., & Montori, V. M. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d5956c · Cited by 48 · cited 1×
“There is good evidence supporting the effectiveness of this approach [28].”
BackgroundMatthews, D. R., & Τσάπας, Α. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.036 · Cited by 47 · cited 1×
“Glycaemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available [1–5], mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycaemic control o…”
BackgroundSelf-citationDavidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46 · cited 1×
“of glycaemic control, recent evidence concerning efficacy and safety of several new drug classes [16, 17], the withdrawal/restriction of others and increasing calls for”
BackgroundJabbour, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01757.x · Cited by 44 · cited 1×
“is frequently required [71].”
Intensified glucose control in type 2 diabetes—whose agenda?
Yudkin, J. S., Richter, B., & Gale, E. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61112-9 · Cited by 43 · cited 1×
“Glycaemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available [1–5], mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycaemic control o…”
BackgroundStrowig, S. M., & Raskin, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00440.x · Cited by 42 · cited 1×
“requirements from severe insulin resistance, these insulin sensitizers may be very helpful in lowering HbA1c and minimising the required insulin dose [96].”
BackgroundRaccah, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00846.x · Cited by 40 · cited 2×
“Therefore, this strategy is somewhat inflexible but may be appropriate for certain patients who eat regularly and may be in need of a simplified approach beyond basal insulin [92, 93].”
BackgroundCounterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
Riddle, M. C. (2010) · Diabetes Care · doi:10.2337/dc10-1658 · Cited by 38 · cited 1×
“It remains unknown whether hypoglycaemia was the cause of the increased mortality in the intensive group [130, 131].”
BackgroundMonogenic diabetes: implications for therapy of rare types of disease
Malecki, M. T., & Mlynarski, W. M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00736.x · Cited by 32 · cited 1×
“There are few exceptions, mainly involving diabetes monogenic variants often confused with type 2 diabetes, such as maturity-onset diabetes of the young (MODY), several forms of which respond preferentially to sulfonylureas [110].”
BackgroundThe Treat-to-Target Trial and Related Studies
Riddle, M. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.71 · Cited by 30 · cited 2×
“The latter two are associated with modestly less overnight hypoglycaemia (insulin glargine, insulin detemir) than NPH and possibly slightly less weight gain (insulin detemir), but are more expensive [75, 76].”
BackgroundBell, D. S. H., Dharmalingam, M., Kumar, S., & Sawakhande, R. B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01408.x · Cited by 28 · cited 1×
“two-drug combination that is not yet or no longer achieving the glycaemic target [83–86].”
BackgroundSulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 26 · cited 1×
“In very preliminary reports, therapy with GLP-1 receptor agonists and DPP-4 inhibitors has been associated with improvement in either cardiovascular risk or risk factors, but there are no long-term data regarding clinical outcomes [113].”
BackgroundInternational Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21 · cited 1×
“It may therefore be justified to start directly with a combination of two noninsulin agents or with insulin itself in this circumstance [78].”
BackgroundSelf-citationConsensus guidelines, algorithms and care of the individual patient with type 2 diabetes
Nolan, J. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1767-z · Cited by 20 · cited 1×
“specific role of each drug, the patient and disease factors that drive clinical decision-making [20–23] and the constraints imposed by age and co-morbidity [4, 6].”
BackgroundIndividualizing treatment targets in diabetes care
Buse, J. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.230 · Cited by 18 · cited 1×
“Data concerning the glycaemic benefits of incretin-based therapy combined with basal insulin are accumulating; combination with GLP1 receptor agonists may be helpful in some patients [97, 98].”
BackgroundSelf-citationThe importance of titrating starting insulin regimens in patients with type 2 diabetes
Garber, A. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01138.x · Cited by 17 · cited 1×
“After the insulin dose is stabilised, the frequency of monitoring should be reviewed [90].”
Background(2009) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(09)33009-9 · Cited by 17
Severe iatrogenic hypoglycemia in type 2 diabetes mellitus
Cryer, P. E. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0355 · Cited by 16 · cited 1×
“Even occasional hypoglycaemia may be devastating, if severe, or merely irritating, if mild [81].”
BackgroundThe combinatorics of medications precludes evidence-based algorithms for therapy
Rodbard, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1904-8 · Cited by 9 · cited 1×
“and permutations would be impossibly large [133].”
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
“apply a patient-centered approach to selection of agents after metformin in patients with type 2 DM.(136) In this manner, the”
MethodInfluentialCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Clinic (US)
- University of North Carolina at Chapel Hill (US)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Thomas Jefferson University (US)
- Churchill Hospital (GB)
- Corresponding author
- Matthews, D. R.
- Venue
- Diabetologia
- Published
- 2012-04-20
- Volume
- 55
- Issue
- 6
- Pages
- 1577-1596
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2111876001
- Cited by
- 3,919
- References
- 149
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 31 · 2023: 32 · 2022: 43 · 2021: 121 · 2020: 160 · 2019: 192 · 2018: 279 · 2017: 375 · 2016: 483 · 2015: 627 · 2014: 776 · 2013: 595 · 2012: 176
- FWCI
- 558.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Yale University
- University of Southern California
- University of Miami
- Wayne State University
- F. Hoffmann-La Roche
- Leona M. and Harry B. Helmsley Charitable Trust
- Georgetown University
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- MedStar Health Research Institute
- Intarcia Therapeutics
- Halozyme
- Dexcom
- National Institute for Health and Care Research (NF-SI-0508-10272)
- University of Sydney
- University of Melbourne
- Vrije Universiteit Amsterdam
- University of Toronto
- Novo Nordisk
- European Association for the Study of Diabetes
- Université de Nantes
- Servier
- University of Ioannina
- National Institutes of Health
- University of Illinois at Urbana-Champaign
- School of Medicine, University of Kansas
- Health Science Center, University of Tennessee
- Leonard M. Miller School of Medicine
- Novartis Pharma
- Abbott Diabetes Care
- Leonard M. Miller School of Medicine, University of Miami
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic control, patient-centered care, treatment guidelines, tight glycemic control, macrovascular complications
- MeSH terms
- Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, Societies, Medical, United States, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.